Physicians' Academy for Cardiovascular Education

BET inhibition in renal and cardiovascular disease: What is the clinical roadmap?

June 5, 2017 - ERA-EDTA, Madrid Spain - Kamyar Kalantar-Zade, MD UC Irvine School of Medicine Irvine, Ca, USA

During a satellite symposium at the ERA-EDTA in Madrid, Spain, organised by PACE-CME, Kamyar Kalantar-Zade, MD shows the data based on which alkaline phosphatase is emerging as a prognostic biomarker of CV events. BET inhibition with apabetalone lowers ALP, and may thus be a promising therapeutic strategy.

Educational information

Faculty & Disclosures

Kamyar Kalantar-Zade, MD UC Irvine School of Medicine Irvine, Ca, USA

CME Accreditation

This lecture was part of a CME accredited symposium: Managing CKD, Diabetes & CVD: Is epigenetics a new way forward? held at ERA-EDTA in Madrid, Spain.

Funding

The symposium was supported by an unrestricted educational grant from Resverlogix Corp